Ignite Creation Date:
2025-12-24 @ 5:38 PM
Ignite Modification Date:
2025-12-27 @ 7:13 AM
Study NCT ID:
NCT00441168
Status:
TERMINATED
Last Update Posted:
2014-03-21
First Post:
2007-02-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
Sponsor:
Janssen-Cilag International NV
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-12
Start Date Type:
None
Primary Completion Date:
2008-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-01
Completion Date Type:
ACTUAL
First Submit Date:
2007-02-27
First Submit QC Date:
None
Study First Post Date:
2007-02-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2009-12-03
Results First Submit QC Date:
None
Results First Post Date:
2014-03-21
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-02-20
Last Update Post Date:
2014-03-21
Last Update Post Date Type:
ESTIMATED